# Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

> **NCT01260844** · PHASE1 · WITHDRAWN · sponsor: **Abbott** · enrollment: 12 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** briakinumab

## Key facts

- **NCT ID:** NCT01260844
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 12 (ESTIMATED)
- **Why stopped:** Study stopped
- **Last updated:** 2011-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260844, "Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01260844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*